Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle.

The polyglutamine disorders are a class of nine neuro-degenerative disorders that are inherited gain-of-function diseases caused by expansion of a translated CAG repeat. Even though the disease-causing proteins are widely expressed, specific collections of neurons are more susceptible in each disease, resulting in characteristic patterns of pathology and clinical symptoms. One hypothesis poses that altered protein function is fundamental to pathogenesis, with protein context of the expanded polyglutamine having key roles in disease-specific processes. This review will focus on the role of the disease-causing polyglutamine proteins in gene transcription and the extent to which the mutant proteins induce disruption of transcription.

[1]  T. Tabata,et al.  Androgen-Dependent Neurodegeneration by Polyglutamine-Expanded Human Androgen Receptor in Drosophila , 2002, Neuron.

[2]  D. Pietrobon,et al.  Calcium channels and channelopathies of the central nervous system , 2002, Molecular Neurobiology.

[3]  Edwin J. Weeber,et al.  SCA7 Knockin Mice Model Human SCA7 and Reveal Gradual Accumulation of Mutant Ataxin-7 in Neurons and Abnormalities in Short-Term Plasticity , 2003, Neuron.

[4]  H. Zoghbi,et al.  Glutamine-Expanded Ataxin-7 Alters TFTC/STAGA Recruitment and Chromatin Structure Leading to Photoreceptor Dysfunction , 2006, PLoS biology.

[5]  M. Sanders,et al.  Autosomal dominant cerebellar ataxia with pigmentary macular dystrophy. A clinical and genetic study of eight families. , 1994, Brain : a journal of neurology.

[6]  Harry T Orr,et al.  Ataxin-1 Nuclear Localization and Aggregation Role in Polyglutamine-Induced Disease in SCA1 Transgenic Mice , 1998, Cell.

[7]  He Li,et al.  Interaction of Huntington Disease Protein with Transcriptional Activator Sp1 , 2002, Molecular and Cellular Biology.

[8]  Olaf Riess,et al.  Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17) , 2003, Annals of neurology.

[9]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[10]  B. Schmidt,et al.  Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. , 2002, Neurology.

[11]  K. Hofmann,et al.  Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. , 2003, Human molecular genetics.

[12]  B. O’Malley,et al.  Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription? , 2004, Molecular endocrinology.

[13]  Làszlò Tora,et al.  Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. , 2004, Human molecular genetics.

[14]  D. Chakravarti,et al.  Ataxin-3 Is a Histone-binding Protein with Two Independent Transcriptional Corepressor Activities* , 2002, The Journal of Biological Chemistry.

[15]  H. Paulson,et al.  Poly-ubiquitin Binding by the Polyglutamine Disease Protein Ataxin-3 Links Its Normal Function to Protein Surveillance Pathways* , 2004, Journal of Biological Chemistry.

[16]  H. Zoghbi,et al.  SUMOylation of the Polyglutamine Repeat Protein, Ataxin-1, Is Dependent on a Functional Nuclear Localization Signal* , 2005, Journal of Biological Chemistry.

[17]  Giuseppe Nicastro,et al.  The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Ruth Luthi-Carter,et al.  Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice , 2003, The Journal of Neuroscience.

[19]  William B. Dobyns,et al.  Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α1A-voltage-dependent calcium channel , 1997, Nature Genetics.

[20]  J. Yates,et al.  Polyglutamine-expanded spinocerebellar ataxia-7 protein disrupts normal SAGA and SLIK histone acetyltransferase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  I. Kanazawa,et al.  PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival. , 1999, Human molecular genetics.

[22]  Barrington G. Burnett,et al.  The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. , 2003, Human molecular genetics.

[23]  P. Pandolfi,et al.  SUMO Modification of Huntingtin and Huntington's Disease Pathology , 2004, Science.

[24]  D. Rubinsztein,et al.  Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.

[25]  H. Zoghbi,et al.  Expression analysis of the ataxin–1 protein in tissues from normal and spinocerebellar ataxia type 1 individuals , 1995, Nature Genetics.

[26]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[27]  M. Privalsky,et al.  The role of corepressors in transcriptional regulation by nuclear hormone receptors. , 2004, Annual review of physiology.

[28]  K. Fischbeck,et al.  Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy , 1991, Nature.

[29]  Y. Agid,et al.  Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion , 1997, Nature Genetics.

[30]  南山 誠.  Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy , 2005 .

[31]  Leslie M Thompson,et al.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  I. Kanazawa,et al.  Interaction between Mutant Ataxin-1 and PQBP-1 Affects Transcription and Cell Death , 2002, Neuron.

[33]  G. Sobue,et al.  Testosterone Reduction Prevents Phenotypic Expression in a Transgenic Mouse Model of Spinal and Bulbar Muscular Atrophy , 2002, Neuron.

[34]  Juan Botas,et al.  The AXH Domain of Ataxin-1 Mediates Neurodegeneration through Its Interaction with Gfi-1/Senseless Proteins , 2005, Cell.

[35]  S. Batalov,et al.  Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Effat S. Emamian,et al.  Serine 776 of Ataxin-1 Is Critical for Polyglutamine-Induced Disease in SCA1 Transgenic Mice , 2003, Neuron.

[37]  K. Yamamoto,et al.  Continuous recycling: a mechanism for modulatory signal transduction. , 2001, Trends in biochemical sciences.

[38]  G. Sobue,et al.  Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy , 2003, Nature Medicine.

[39]  Huda Y. Zoghbi,et al.  Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1 , 1993, Nature Genetics.

[40]  Pier Paolo Di Fiore,et al.  Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Dejean,et al.  Nuclear and unclear functions of SUMO , 2003, Nature Reviews Molecular Cell Biology.

[42]  S. Müller,et al.  SUMO: a regulator of gene expression and genome integrity , 2004, Oncogene.

[43]  H. Lehrach,et al.  Ataxin-3 is transported into the nucleus and associates with the nuclear matrix. , 1998, Human molecular genetics.

[44]  T. Klockgether,et al.  SCA6 is caused by moderate CAG expansion in the alpha1A-voltage-dependent calcium channel gene. , 1997, Human molecular genetics.

[45]  Mihoro Saeki,et al.  Association of Two Nuclear Proteins, Npw38 and NpwBP, via the Interaction between the WW Domain and a Novel Proline-rich Motif Containing Glycine and Arginine* , 1999, The Journal of Biological Chemistry.

[46]  Erica S. Johnson,et al.  Protein modification by SUMO. , 2004, Annual review of biochemistry.

[47]  Jonathan Gray,et al.  Rb regulates proliferation and rod photoreceptor development in the mouse retina , 2004, Nature Genetics.

[48]  D. Housman,et al.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.

[49]  C. Ware,et al.  Polyglutamine-Expanded Ataxin-7 Antagonizes CRX Function and Induces Cone-Rod Dystrophy in a Mouse Model of SCA7 , 2001, Neuron.

[50]  M. Hayden,et al.  Nuclear Localization of a Non-caspase Truncation Product of Atrophin-1, with an Expanded Polyglutamine Repeat, Increases Cellular Toxicity* , 2003, The Journal of Biological Chemistry.

[51]  V. Laudet,et al.  The nuclear receptor superfamily , 2003, Journal of Cell Science.

[52]  T. Maniatis,et al.  An extensive network of coupling among gene expression machines , 2002, Nature.

[53]  M. Beal,et al.  The Energetics of Huntington's Disease , 2004, Neurochemical Research.

[54]  W. Alaynick,et al.  Boat, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin‐1 , 2005, The EMBO journal.

[55]  Dimitri Krainc,et al.  Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease , 2002, Science.

[56]  A. Smith,et al.  Müller-cell-derived leukaemia inhibitory factor arrests rod photoreceptor differentiation at a postmitotic pre-rod stage of development. , 1997, Development.

[57]  Tian Xu,et al.  Drosophila Atrophin Homolog Functions as a Transcriptional Corepressor in Multiple Developmental Processes , 2002, Cell.

[58]  R. Tjian,et al.  Coactivators and TAFs: a new class of eukaryotic transcription factors that connect activators to the basal machinery. , 1993, Cold Spring Harbor symposia on quantitative biology.

[59]  C. Gomez,et al.  C-termini of P/Q-type Ca2+ channel alpha1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity. , 2006, Human molecular genetics.

[60]  C A Ross,et al.  Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity , 2001, Science.

[61]  Harry T Orr,et al.  RNA association and nucleocytoplasmic shuttling by ataxin-1 , 2005, Journal of Cell Science.

[62]  Huda Y. Zoghbi,et al.  Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1 , 2000, Nature Neuroscience.

[63]  R. Tjian,et al.  In Vitro Analysis of Huntingtin-Mediated Transcriptional Repression Reveals Multiple Transcription Factor Targets , 2005, Cell.

[64]  R. Reed,et al.  Coupling transcription, splicing and mRNA export. , 2003, Current opinion in cell biology.

[65]  H. Zoghbi,et al.  Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice. , 2004, Human molecular genetics.

[66]  H. Paulson,et al.  Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. , 2005, Molecular cell.

[67]  Denise S Walker,et al.  Subunit interaction sites in voltage-dependent Ca2+ channels: role in channel function , 1998, Trends in Neurosciences.

[68]  K. Borden,et al.  Pondering the Promyelocytic Leukemia Protein (PML) Puzzle: Possible Functions for PML Nuclear Bodies , 2002, Molecular and Cellular Biology.

[69]  Robert Tjian,et al.  Eukaryotic coactivators associated with the TATA box binding protein , 1992 .

[70]  S Kobayashi,et al.  A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? , 1999, Human molecular genetics.

[71]  M. Beal,et al.  Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease* , 2005, Journal of Biological Chemistry.

[72]  D. Housman,et al.  Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[73]  R. E. Hughes.  Polyglutamine Disease: Acetyltransferases Awry , 2002, Current Biology.

[74]  L. Goldstein,et al.  Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. , 2005, Archives of neurology.

[75]  Hung-Ying Kao,et al.  Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[77]  C. Ross,et al.  Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.

[78]  H. Zoghbi,et al.  Identification of genes that modify ataxin-1-induced neurodegeneration , 2000, Nature.

[79]  H. Orr,et al.  Beyond the Qs in the polyglutamine diseases. , 2001, Genes & development.

[80]  B. Chait,et al.  Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.